From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Other namesRaxatrigine; CNV1014802; GSK-1014802; BIIB 074
Routes of
By mouth
ATC code
  • None
CAS Number
PubChem CID
Chemical and physical data
Molar mass314.354 g/mol g·mol−1
3D model (JSmol)

Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[citation needed] Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker.[citation needed] As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.[4]

See also[edit]


  1. ^ Convergence Pharmaceuticals. "CNV1014802 - Convergence Pharmaceuticals".
  2. ^ Stephen McMahon; Martin Koltzenburg; Irene Tracey; Dennis C. Turk (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.
  3. ^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.
  4. ^ a b

External links[edit]